Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 7/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | RELA | Q04206 | 2/20 | 0.42 |
| ▸ | MDM4 | O15151 | 1/20 | 0.42 |
| ▸ | NFKBIA | P25963 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.42 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.42 |
| ▸ | RAB9A | P51151 | 4/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3628262 | 0.80 | MEN1 (0.51) | PDE10AMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL1702526 | 0.78 | XPO1 (0.48) | MAPTKMT2AL3MBTL1TDP1RELA | |
| SCHEMBL1705792 | 0.78 | TSHR (0.55) | MAPTALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL22146976 | 0.78 | XPO1 (0.42) | MAPTALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL20913332 | 0.77 | FGFR1 (0.47) | PDE10AMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL1702768 | 0.77 | DHODH (0.57) | MAPTALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL16388912 | 0.76 | DHODH (0.47) | MAPTALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL11554972 | 0.76 | GRM5 (0.58) | PDE10AMAPTMEN1KMT2AL3MBTL1 | |
| SCHEMBL20924428 | 0.75 | KMT2A (0.45) | MAPTALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL13506822 | 0.75 | L3MBTL1 (0.65) | MAPTALDH1A1MEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2440546-B1 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | ABIVAX (FR) | 2022-12-28 | — | — | EP | claimed |
| EP-2440547-B1 | New chemical molecules that inhibit the splicing mechanism for the treatment of diseases resulting from splicing defects | ABIVAX (FR) | 2022-11-30 | — | — | EP | claimed |
| EP-2440545-B1 | COMPOUNDS USEFUL FOR TREATING CANCER | ABIVAX (FR) | 2019-04-24 | — | — | EP | claimed |
| US-9908869-B2 | Compounds useful for treating aids | ABIVAX (FR) | 2018-03-06 | — | — | US | claimed |
| US-9827237-B2 | Compounds useful for treating diseases caused by retroviruses | ABIVAX (FR) | 2017-11-28 | — | — | US | claimed |
| US-20160151348-A1 | COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | ABIVAX (FR) | 2016-06-02 | — | — | US | claimed |
| EP-3016656-A1 | BICYCLIC COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | ABIVAX (FR) | 2016-05-11 | — | — | EP | claimed |
| US-9108919-B2 | Compounds useful for treating cancer | ABIVAX (FR) | 2015-08-18 | — | — | US | claimed |
| WO-2015001518-A1 | BICYCLIC COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | SPLICOS (FR) | 2015-01-08 | — | — | WO | claimed |
| US-20140288120-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | SOCIETE SPLICOS (FR) | 2014-09-25 | — | — | US | claimed |
| US-20140080831-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | CENTRE NATIONALE DE RECHERCHE SCIENTIFIQUE (FR) | 2014-03-20 | — | — | US | claimed |
| US-20120329796-A1 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | SOCIETE SPLICOS (FR) | 2012-12-27 | — | — | US | claimed |
| US-20120283265-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | SOCIETE SPLICOS (FR) | 2012-11-08 | — | — | US | claimed |
| US-20120277230-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | SOCIETE SPLICOS (FR) | 2012-11-01 | — | — | US | claimed |
| WO-2010143169-A2 | COMPOUNDS USEFUL FOR TREATING AIDS | SOCIÉTÉ SPLICOS (FR) | 2010-12-16 | — | — | WO | claimed |
| WO-2010143170-A2 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | SOCIÉTÉ SPLICOS (FR) | 2010-12-16 | — | — | WO | claimed |
| US-20240343716-A1 | COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING | ABIVAX (FR) | 2024-10-17 | — | — | US | disclosed |
| EP-3517534-B1 | COMPOUNDS USEFUL FOR TREATING CANCER | ABIVAX (FR) | 2024-02-28 | — | — | EP | disclosed |
| WO-2010143169-A2 | COMPOUNDS USEFUL FOR TREATING AIDS | SOCIÉTÉ SPLICOS (FR) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010143169-A2 | COMPOUNDS USEFUL FOR TREATING AIDS | SOCIÉTÉ SPLICOS (FR) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283265-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | CBR1, CNR1, CBR3 | PDE10A 3772/4885MAPT 4329/4885ALDH1A1 1177/4885 |
| US-20140288120-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | NR1H3, NR3C1, NR3C2 | PDE10A 3381/4885MAPT 4252/4885ALDH1A1 1139/4885 |
| US-20120277230-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | CBR1, CBR3, NCOR1 | PDE10A 4570/4885MAPT 4736/4885ALDH1A1 1416/4885 |
| US-20240343716-A1 | COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING | RCOR1, NR3C1, NR5A1 | PDE10A 3850/4885MAPT 3932/4885ALDH1A1 342/4885 |
| US-20120329796-A1 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | NR2C2, NCOR2, NR4A2 | PDE10A 2845/4885MAPT 4162/4885ALDH1A1 2642/4885 |
| US-20160151348-A1 | COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | RCOR1, CBR1, RCOR3 | PDE10A 4667/4885MAPT 3658/4885ALDH1A1 3191/4885 |
| US-20140080831-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | NR1H4, NR1H3, NCOR1 | PDE10A 4193/4885MAPT 4707/4885ALDH1A1 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.